JP2010512324A5 - - Google Patents

Download PDF

Info

Publication number
JP2010512324A5
JP2010512324A5 JP2009540318A JP2009540318A JP2010512324A5 JP 2010512324 A5 JP2010512324 A5 JP 2010512324A5 JP 2009540318 A JP2009540318 A JP 2009540318A JP 2009540318 A JP2009540318 A JP 2009540318A JP 2010512324 A5 JP2010512324 A5 JP 2010512324A5
Authority
JP
Japan
Prior art keywords
peptide
amino acid
antibody
fragment
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009540318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512324A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/025105 external-priority patent/WO2008073312A2/en
Publication of JP2010512324A publication Critical patent/JP2010512324A/ja
Publication of JP2010512324A5 publication Critical patent/JP2010512324A5/ja
Pending legal-status Critical Current

Links

JP2009540318A 2006-12-08 2007-12-07 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法 Pending JP2010512324A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87362706P 2006-12-08 2006-12-08
US93003407P 2007-05-11 2007-05-11
PCT/US2007/025105 WO2008073312A2 (en) 2006-12-08 2007-12-07 Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014154804A Division JP6019457B2 (ja) 2006-12-08 2014-07-30 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2010512324A JP2010512324A (ja) 2010-04-22
JP2010512324A5 true JP2010512324A5 (enExample) 2011-02-03

Family

ID=39512272

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009540318A Pending JP2010512324A (ja) 2006-12-08 2007-12-07 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法
JP2014154804A Active JP6019457B2 (ja) 2006-12-08 2014-07-30 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014154804A Active JP6019457B2 (ja) 2006-12-08 2014-07-30 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法

Country Status (9)

Country Link
US (1) US8105602B2 (enExample)
EP (1) EP2117571B1 (enExample)
JP (2) JP2010512324A (enExample)
CA (1) CA2671971C (enExample)
DK (1) DK2117571T3 (enExample)
ES (1) ES2636451T3 (enExample)
PL (1) PL2117571T3 (enExample)
PT (1) PT2117571T (enExample)
WO (1) WO2008073312A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070047246A (ko) * 2004-05-25 2007-05-04 아테뉴온, 엘엘씨 유로키나아제형 플라스미노겐 활성인자(uPA)와 그의수용체(uPAR)의 복합체에 결합하여 하류 uPAR상호작용을 억제하는 리간드의 동정 및 진단 또는치료에서의 용도
US8105602B2 (en) 2006-12-08 2012-01-31 Tactic Pharma, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
US8697081B2 (en) * 2008-04-09 2014-04-15 The Regents Of The University Of Michigan Method of modulating neovascularization
WO2011028531A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
PT2510012T (pt) * 2009-12-09 2017-07-13 Bayer Pharma AG Anticorpos anti-c4.4a e utilizações dos mesmos
EP2534179A4 (en) * 2010-02-12 2013-07-17 Univ California UPAR BINDING AGENT AND METHOD FOR THEIR USE
BR112013016107A2 (pt) 2010-12-22 2017-04-04 Ifom Fond Inst Firc Di Oncologia Molecolare molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
CN103930128A (zh) 2011-08-05 2014-07-16 意大利癌症研究基金会分子肿瘤学研究所(Ifom) 组成型活性uPAR变体及其在抑制性抗体的生成与分离中的应用
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
WO2015004148A1 (en) 2013-07-08 2015-01-15 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
WO2015017386A1 (en) * 2013-08-01 2015-02-05 The General Hospital Corporation NON-GLYCOSYLATED suPAR BIOMARKERS AND USES THEREOF
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG10202112047TA (en) 2015-09-18 2021-12-30 Baylor College Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7140362B2 (ja) * 2018-04-09 2022-09-21 国立大学法人東海国立大学機構 活性型組換えアクロシン
CN115867570A (zh) * 2020-06-15 2023-03-28 莫诺帕医疗公司 精确放射免疫治疗靶向尿激酶纤溶酶原激活剂受体(uPAR)以治疗严重COVID-19疾病
EP4341265A4 (en) * 2021-05-21 2025-07-23 Northstar Medical Tech Llc TRIVALENT RADIOISTOPE BIO-TARGETED RADIOPHARMACEUTICAL, METHODS OF PREPARATION AND USE
CN116410312A (zh) * 2021-12-29 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型upar单域抗体的开发
EP4490511A2 (en) * 2022-03-07 2025-01-15 Rush University Medical Center Novel treatment of diabetes and kidney disease by inhibition of d2d3 a proteolytic upar protein
CN117264061B (zh) * 2023-11-22 2024-03-01 中山大学附属第八医院(深圳福田) 一种识别uPAR的纳米抗体及其应用
WO2025207781A1 (en) 2024-03-26 2025-10-02 Monopar Therapeutics Inc. Antibody radioisotope constructs

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8721023D0 (en) 1987-09-07 1987-10-14 Lepetit Spa Modified plasminogen activators
IT1228881B (it) 1988-08-12 1991-07-09 Lepetit Spa Anticorpo monoclonale specifico per l'epitopo dell'urochinasi prourichinasi corrispondente alla regione denominata gfd
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
DE69033653T2 (de) * 1989-04-07 2001-06-07 Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimental Cancerforskning), Kopenhagen Plasminogen-aktivator-rezeptor vom urokinasetyp
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
CA2094276C (en) 1990-10-18 2005-08-23 Keld Dano Antibodies against the urokinase receptor and their use
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
JPH07501524A (ja) 1991-11-18 1995-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン uPA−Rの検出・分離方法及びuPAのuPA−Rへの結合阻止方法
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
ES2143504T3 (es) 1992-05-28 2000-05-16 Univ Toledo Uso de un material citotoxico acoplado a un material inhibidor del activador plasminogeno para la produccion de un medicamento para el tratamiento de celulas cancerigenas.
US5608110A (en) * 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
WO1995004281A1 (en) * 1993-07-27 1995-02-09 THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Quantitative method of measuring cancer cell urokinase and metastatic potential
US5532132A (en) * 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
JP2852192B2 (ja) * 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・1989(フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング) uPARのドメイン2+3のuPA結合部位および抗体
US5618513A (en) * 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
KR100497017B1 (ko) 1996-03-22 2005-11-29 휴먼 게놈 사이언시즈, 인코포레이티드 고사유도분자ii
EP1042343B1 (en) 1997-11-03 2008-01-23 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
US6077508A (en) 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
DE50015293D1 (de) 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
DE60219888T2 (de) 2001-01-25 2008-01-17 Fondazione Centro San Raffaele Del Monte Tabor Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
US6846484B2 (en) 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
ATE524739T1 (de) 2002-02-13 2011-09-15 American Diagnostica Inc Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten
WO2003079974A2 (en) * 2002-03-18 2003-10-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona Integrin ligand
KR100470535B1 (ko) 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
WO2004099780A1 (en) 2003-05-06 2004-11-18 Rigshospitalet Immunoassays for the detection of urokinase receptor forms
CA2546237A1 (en) 2003-11-18 2005-06-02 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
US7541159B2 (en) * 2004-04-14 2009-06-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Molecular-specific urokinase antibodies
KR20070047246A (ko) 2004-05-25 2007-05-04 아테뉴온, 엘엘씨 유로키나아제형 플라스미노겐 활성인자(uPA)와 그의수용체(uPAR)의 복합체에 결합하여 하류 uPAR상호작용을 억제하는 리간드의 동정 및 진단 또는치료에서의 용도
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
US8105602B2 (en) 2006-12-08 2012-01-31 Tactic Pharma, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2010512324A5 (enExample)
JP7610541B2 (ja) 結合タンパク質及びその使用方法
US11959924B2 (en) Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample
HRP20160857T1 (hr) Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene
JP5438095B2 (ja) グルカゴン受容体アンタゴニスト
Hutamekalin et al. Collagen antibody-induced arthritis in mice: development of a new arthritogenic 5-clone cocktail of monoclonal anti-type II collagen antibodies
JP2007530068A5 (enExample)
RU2011149334A (ru) Анти-il-17f антитела и способы их применения
JP2012523848A5 (enExample)
JP2014224134A5 (enExample)
JP2009297037A5 (enExample)
HRP20130883T4 (hr) Međuvrsno specifična cd3-epsilon-vežuća domena
JP2007527406A5 (enExample)
JP2015519055A5 (enExample)
RS54685B1 (sr) ANTI-N3pGlu AMILOID BETA PEPTID ANTITELA I NJIHOVE UPOTREBE
JP2011526249A5 (enExample)
CA2604357A1 (en) P-cadherin antibodies
JP2012530487A5 (enExample)
WO2022135536A1 (zh) Cd3人源化抗体及其应用
TWI688575B (zh) 阻礙血管內皮脂酶之酵素活性的人類化單株抗體
Rasmussen et al. A novel antihuman C3d monoclonal antibody with specificity to the C3d complement split product
JP2024546028A (ja) L-チロキシンに対する新規なモノクローナル抗体およびその診断的使用
CA3212098A1 (en) Stem cell factor antibodies and methods of use thereof
US20090117122A1 (en) Resistin Antagonists and Their Use
US10584175B2 (en) FN14-binding proteins and uses thereof